Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review

Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review

Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Until recently, cytotoxic chemotherapy was the only treatment option. Currently, there are subgroups of patients with PDAC either with somatic or germline mutations who are candidates for targeted agents. Germline mutations i...

Full description

Bibliographic Details
Main Authors: Jefferson Rios Pimenta, Serli Kiyomi Nakao Ueda, Renata D’Alpino Peixoto
Format: Article
Language:English
Published: Karger Publishers 2020-07-01
Series:Case Reports in Oncology
Subjects:
pancreatic adenocarcinoma
germline mutations
brca
parp-inhibitor
platinum sensitiveness
folfirinox
Online Access:https://www.karger.com/Article/FullText/508533

Similar Items

Similar Items